Carmona Herrera F

No ORCID on file · 4 papers in corpus · active 2024-2026

Study types

  • other 3
  • rct 1

Condition tags

  • endometriosis 3
  • dysmenorrhea 2
  • dyspareunia 2
  • chronic_pelvic_pain 1
other 2026
Linzagolix, with and without add-back therapy, in women with endometriosis-associated pain: results from EDELWEISS 6, a double-blind randomized extension and withdrawal study
Human reproduction open ·doi:10.1093/hropen/hoag030

STUDY QUESTION: Was the efficacy of linzagolix, observed at 6 months in women with endometriosis-associated pain, maintained when administered for an additional 6 months? SUMMARY ANSWER: Efficacy from this extension study complements the r…

other 2025
Two-year follow-up study (PRIMROSE 3) to assess bone mineral density in subjects with uterine fibroids completing the PRIMROSE 1 and PRIMROSE 2 linzagolix trials
Human reproduction open ·doi:10.1093/hropen/hoaf025

STUDY QUESTION: How important was the change in lumbar spine (L1-L4), femoral neck, and total hip bone mineral density (BMD) from post-treatment baseline values to 24 months after the end of treatment in PRIMROSE 1 and PRIMROSE 2 study part…

rct 2024
Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3)
Human Reproduction ·doi:10.1093/humrep/deae076

STUDY QUESTION: Does linzagolix administered orally once daily for up to 3 months at a dose of 75 mg alone or 200 mg in combination with add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethindrone acetate, also known as norethisterone ac…

other 2024
Reply: Missing the target
Human Reproduction ·doi:10.1093/humrep/deae223